CLINICAL TRIALS PROFILE FOR SURFAXIN
✉ Email this page to a colleague
All Clinical Trials for SURFAXIN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00215540 ↗ | SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants. | Terminated | Windtree Therapeutics | Phase 2 | 2005-02-01 | SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required continued intubation and received surfactants for the prevention or treatment of respiratory distress syndrome (RDS). |
NCT00215553 ↗ | KL₄Surfactant Treatment in Patients With ARDS | Terminated | Windtree Therapeutics | Phase 2 | 2001-05-01 | Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory distress syndrome(ARDS). |
NCT00807235 ↗ | Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants | Terminated | Windtree Therapeutics | Phase 2 | 2005-01-01 | To evaluate the feasibility, safety and tolerability of aerosolized lucinactant delivered by nasal continuous positive airway pressure (nCPAP) for the prevention of respiratory distress syndrome (RDS) in premature infants. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SURFAXIN
Condition Name
Clinical Trial Locations for SURFAXIN
Trials by Country
Clinical Trial Progress for SURFAXIN
Clinical Trial Phase
Clinical Trial Sponsors for SURFAXIN
Sponsor Name